相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Linaclotide, Novel Therapy for the Treatment of Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome
Maria I. Vazquez-Roque et al.
ADVANCES IN THERAPY (2013)
Inhibition of p38/Mk2 signaling pathway improves the anti-inflammatory effect of WIN55 on mouse experimental colitis
Yu Y. Li et al.
LABORATORY INVESTIGATION (2013)
Cannabinoid Receptor 1 in the Vagus Nerve Is Dispensable for Body Weight Homeostasis But Required for Normal Gastrointestinal Motility
Claudia R. Vianna et al.
JOURNAL OF NEUROSCIENCE (2012)
The Gastrointestinal Pharmacology of Cannabinoids: Focus on Motility
Raquel Abalo et al.
PHARMACOLOGY (2012)
Medical Management of Constipation
Meredith Portalatin et al.
Clinics in Colon and Rectal Surgery (2012)
Current and future therapies for chronic constipation
J. Tack
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2011)
Alternative targets within the endocannabinoid system for future treatment of gastrointestinal diseases
Rudolf Schicho et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY (2011)
Neuropsychiatric Adverse Effects of Centrally Acting Antiobesity Drugs
Pradeep J. Nathan et al.
CNS NEUROSCIENCE & THERAPEUTICS (2011)
Lubiprostone for the Treatment of Adults with Constipation and Irritable Bowel Syndrome
Ron Schey et al.
DIGESTIVE DISEASES AND SCIENCES (2011)
Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study
S. Fukudo et al.
NEUROGASTROENTEROLOGY AND MOTILITY (2011)
Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation
Maria Vazquez Roque et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2011)
Pharmacotherapies for Obesity: Past, Current, and Future Therapies
Lisa L. Ioannides-Demos et al.
JOURNAL OF OBESITY (2011)
A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes
M. S. Kipnes et al.
DIABETES OBESITY & METABOLISM (2010)
Relapse prevention in UK Stop Smoking Services: current practice, systematic reviews of effectiveness and cost-effectiveness analysis
T. Coleman et al.
HEALTH TECHNOLOGY ASSESSMENT (2010)
A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study
L. J. Aronne et al.
INTERNATIONAL JOURNAL OF OBESITY (2010)
A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study
J. Proietto et al.
INTERNATIONAL JOURNAL OF OBESITY (2010)
Central and peripheral consequences of the chronic blockade of CB1 cannabinoid receptor with rimonabant or taranabant
Elena Martin-Garcia et al.
JOURNAL OF NEUROCHEMISTRY (2010)
Synthesis and biological evaluation of novel peripherally active morphiceptin analogs
Katarzyna Gach et al.
PEPTIDES (2010)
Cannabinoid-1 (CB1) receptors regulate colonic propulsion by acting at motor neurons within the ascending motor pathways in mouse colon
Andrei Sibaev et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2009)
Lubiprostone In Constipation-Predominant Irritable Bowel Syndrome
Natalie J. Carter et al.
DRUGS (2009)
Activation of the Cannabinoid 2 Receptor (CB2) Protects Against Experimental Colitis
Martin A. Storr et al.
INFLAMMATORY BOWEL DISEASES (2009)
Salvinorin A inhibits colonic transit and neurogenic ion transport in mice by activating κ-opioid and cannabinoid receptors
J. Fichna et al.
NEUROGASTROENTEROLOGY AND MOTILITY (2009)
The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake
Carol Addy et al.
CELL METABOLISM (2008)
The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome
M. A. Storr et al.
NEUROGASTROENTEROLOGY AND MOTILITY (2008)
Irritable bowel syndrome
Emeran A. Mayer
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Antidepressant-like effect of endomorphin-1 and endomorphin-2 in mice
Jakub Fichna et al.
NEUROPSYCHOPHARMACOLOGY (2007)
The additive antinociceptive interaction between WIN 55,212-2, a cannabinoid agonist, and ketorolac
A Ulugöl et al.
ANESTHESIA AND ANALGESIA (2006)
Irritable bowel syndrome - Recent and novel therapeutic approaches
Viola Andresen et al.
DRUGS (2006)
The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract
F Massa et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2005)
Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents
G Griebel et al.
BIOLOGICAL PSYCHIATRY (2005)
Cannabinoid receptor type 1 modulates excitatory and inhibitory neurotransmission in mouse colon
M Storr et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2004)
The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions
ET Tzavara et al.
BRITISH JOURNAL OF PHARMACOLOGY (2003)
Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice
LP Shearman et al.
BEHAVIOURAL PHARMACOLOGY (2003)
Structural differences in the enteric neural network in murine colon: impact on electrophysiology
A Sibaev et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2003)
Tegaserod - A review of its use in the management of irritable bowel syndrome with constipation in women
AJ Wagstaff et al.
DRUGS (2003)
AGA technical review on irritable bowel syndrome
DA Drossman et al.
GASTROENTEROLOGY (2002)
American gastroenterological association medical position statement: Irritable bowel syndrome
GASTROENTEROLOGY (2002)
A new model of visceral pain and referred hyperalgesia in the mouse
JMA Laird et al.
PAIN (2001)
分享论文
